Article
Infectious Diseases
Diana Leticia Coronel-Martinez, Juliana Park, Eduardo Lopez-Medina, Maria Rosario Capeding, Andres Angelo Cadena Bonfanti, Maria Cecilia Montalban, Isabel Ramirez, Maria Liza Antoinette Gonzales, Betzana Zambrano, Gustavo Dayan, Zhenghong Chen, Hao Wang, Matthew Bonaparte, Andrey Rojas, Jenny Carolina Ramirez, Mae Ann Verdan, Fernando Noriega
Summary: This study aimed to assess the need for a CYD-TDV booster after different primary vaccination regimens. The results showed that a CYD-TDV booster 1 year or 2 years after the two-dose or three-dose primary vaccination regimen did not elicit a consistent, meaningful booster effect against all dengue serotypes in participants who were seropositive for dengue at baseline.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Lei Wang, Zhiwei Wu, Zhifang Ying, Minjie Li, Yuansheng Hu, Qun Shu, Jing Li, Huixian Wang, Hengming Zhang, Wenbin Jiao, Lin Wang, Yuliang Zhao, Qiang Gao
Summary: This study evaluates the safety and immunogenicity of a third dose of the CoronaVac vaccine in children and adolescents. The results show that a third dose is safe and increases neutralizing antibody levels significantly.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Jakub Wronski, Bozena Jaszczyk, Leszek Roszkowski, Anna Felis-Giemza, Krzysztof Bonek, Anna Kornatka, Magdalena Plebanczyk, Tomasz Burakowski, Barbara Lisowska, Brygida Kwiatkowska, Wlodzimierz Maslinski, Malgorzata Wislowska, Magdalena Massalska, Marzena Ciechomska, Ewa Kuca-Warnawin
Summary: Patients with inflammatory arthritis show lower humoral and cellular responses after receiving the COVID-19 booster vaccine compared to healthy controls. Immunomodulatory drugs may impact the immune response post booster vaccination.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Supachaya Sriphoosanaphan, Sirinporn Suksawatamnuay, Nunthiya Srisoonthorn, Nipaporn Siripon, Panarat Thaimai, Prooksa Ananchuensook, Kessarin Thanapirom, Bunthoon Nonthasoot, Pokrath Hansasuta, Piyawat Komolmit
Summary: Heterologous prime-boost vaccination with ChAdOx1/BNT162b2 induced significantly higher immune response than ChAdOx1/ChAdOx1 in liver transplant recipients. The booster vaccination strategy resulted in robust immunity against the wild type virus in most patients but was less effective against the Omicron variant.
Article
Immunology
Supattra Rungmaitree, Charin Thepthai, Zheng Quan Toh, Noppasit Musiwiraphat, Alan Maleesatharn, Rattanachai Rermruay, Sathida Sungkate, Wanatpreeya Phongsamart, Keswadee Lapphra, Orasri Wittawatmongkol, Tararaj Dharakul, Kim Mulholland, Kulkanya Chokephaibulkit
Summary: In HIV-infected adolescents with immune reconstitution, a two-dose HPV vaccination schedule is as immunogenic as a three-dose schedule.
Review
Pharmacology & Pharmacy
Xin Chen, Ruyue He, Xinyi Chen, Liyun Jiang, Fei Wang
Summary: Small sample sizes in early-phase clinical trials may not establish clear toxicity and efficacy profiles for dose-schedule regimens. Bayesian adaptive designs offer an effective way to evaluate multiple doses and schedules in a single trial, but their real-world implementation examples are limited. This paper reviews critical factors and innovative Bayesian adaptive designs for dose-schedule optimization, and discusses unresolved issues and future research opportunities.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Immunology
Yael Shachor-Meyouhas, Halima Dabaja-Younis, Avi Magid, Ronit Leiba, Moran Szwarcwort-Cohen, Ronit Almog, Michal Mekel, Avi Weissman, Gila Hyams, Vardit Gepstein, Nethanel A. A. Horowitz, Hagar Cohen Saban, Jalal Tarabeia, Michael Halberthal, Khetam Hussein
Summary: The fourth dose of SARS-CoV-2 vaccine provides protection against infection, severe disease, and death. The risk of symptomatic or severe disease is related to antibody levels, with lower protection against the Omicron variants. This study assesses the impact of the fourth dose on infection and illness perception among healthcare workers and investigates the protective effect of antibody levels.
Article
Mathematical & Computational Biology
Thao M. P. Tran, Steven Abrams, Marc Aerts, Kirsten Maertens, Niel Hens
Summary: Censoring due to detection or quantification limits is common in medical studies. Traditional methods such as substitution and complete case analysis are often biased, while the maximum likelihood estimation (MLE) approach performs well. Using a copula function to join marginal distributions improves estimation of association and outperforms conventional methods in simulations.
STATISTICS IN MEDICINE
(2021)
Article
Infectious Diseases
Daniela Manno, Agnes Bangura, Frank Baiden, Abu Bakarr Kamara, Philip Ayieko, Joseph Kallon, Julie Foster, Musa Conteh, Nicholas Edward Connor, Bockarie Koroma, Yusupha Njie, Paul Borboh, Babajide Keshinro, Bolarinde Joseph Lawal, Mattu Tehtor Kroma, Godfrey Tuda Otieno, Abdul Tejan Deen, Edward Man-Lik Choi, Ahmed Dahiru Balami, Auguste Gaddah, Chelsea McLean, Kerstin Luhn, Hammed Hassan Adetola, Gibrilla Fadlu Deen, Mohamed Samai, Brett Lowe, Cynthia Robinson, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones
Summary: This study aimed to evaluate the safety and immunogenicity of a booster dose of the Ad26.ZEBOV vaccine in children who had been previously vaccinated with a two-dose regimen. The booster dose was well tolerated and significantly increased the levels of Ebola virus-specific antibodies in children. These findings have important implications for Ebola vaccination strategies in pediatric populations.
LANCET INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, Lily Y. Weckx, Pedro M. Folegatti, Parvinder K. Aley, Brian Angus, Vicky L. Baillie, Shaun L. Barnabas, Qasim E. Bhorat, Sagida Bibi, Carmen Briner, Paola Cicconi, Elizabeth A. Clutterbuck, Andrea M. Collins, Clare L. Cutland, Thomas C. Darton, Keertan Dheda, Christina Dold, Christopher J. A. Duncan, Katherine R. W. Emary, Katie J. Ewer, Amy Flaxman, Lee Fairlie, Saul N. Faust, Shuo Feng, Daniela M. Ferreira, Adam Finn, Eva Galiza, Anna L. Goodman, Catherine M. Green, Christopher A. Green, Melanie Greenland, Catherine Hill, Helen C. Hill, Ian Hirsch, Alane Izu, Daniel Jenkin, Carina C. D. Joe, Simon Kerridge, Anthonet Koen, Gaurav Kwatra, Rajeka Lazarus, Vincenzo Libri, Patrick J. Lillie, Natalie G. Marchevsky, Richard P. Marshall, Ana V. A. Mendes, Eveline P. Milan, Angela M. Minassian, Alastair McGregor, Yama F. Mujadidi, Anusha Nana, Sherman D. Padayachee, Daniel J. Phillips, Ana Pittella, Emma Plested, Katrina M. Pollock, Maheshi N. Ramasamy, Adam J. Ritchie, Hannah Robinson, Alexandre V. Schwarzbold, Andrew Smith, Rinn Song, Matthew D. Snape, Eduardo Sprinz, Rebecca K. Sutherland, Emma C. Thomson, M. Estee Torok, Mark Toshner, David P. J. Turner, Johan Vekemans, Tonya L. Villafana, Thomas White, Christopher J. Williams, Alexander D. Douglas, Adrian V. S. Hill, Teresa Lambe, Sarah C. Gilbert, Andrew J. Pollard
Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.
Article
Immunology
Yukai Zhang, Lei Wang, Yanxia Wang, Wei Zhang, Ningning Jia, Zhiqiang Xie, Lili Huang, Wangyang You, Weifeng Lu, Erwei Li, Feilong Gao, Yuansheng Hu, Fanhong Meng, Shengli Xia
Summary: This study evaluated the immunogenicity and safety of Sinovac's attenuated varicella vaccine (VarV) booster dose, as well as the immune persistence of a primary dose in 2- to 6-year-old children. The results showed that VarV had good immune persistence in the 1 to 3 years after primary immunization, and the booster dose recalled a specific immune response to varicella-zoster virus in children aged 1 to 3 years after primary immunization, with no safety concerns increased.
Article
Gastroenterology & Hepatology
Michael G. Bruce, Dana Bruden, Debby Hurlburt, Julie Morris, Sara Bressler, Gail Thompson, Danielle Lecy, Karen Rudolph, Lisa Bulkow, Thomas Hennessy, Brenna C. Simons, Mark K. Weng, Noele Nelson, Brian J. McMahon
Summary: This study examined the long-term protection from hepatitis B vaccination in Alaska Native populations who received the vaccine in 1981. Results showed that the majority of participants still had evidence of protection 35 years later, indicating that booster doses may not be necessary for the general population at this time.
Article
Medicine, General & Internal
Alasdair P. S. Munro, Leila Janani, Victoria Cornelius, Parvinder K. Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Karishma Gokani, Anna L. Goodman, Christopher A. Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A. van der Klaauw, Jonathan Kwok, Teresa Lambe, Vincenzo Libri, Martin J. Llewelyn, Alastair C. McGregor, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama F. Mujadidi, Jennifer Murira, Orod Osanlou, Rostam Osanlou, Daniel R. Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Jo Salkeld, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Ann Sturdy, Emma C. Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape, Xinxue Liu, Saul N. Faust
Summary: In a trial investigating third-dose booster vaccinations of different COVID-19 vaccines, it was found that all study vaccines boosted antibody and neutralizing responses after initial ChAd/ChAd and BNT/BNT vaccinations, with no safety concerns. There were substantial differences in humoral and cellular responses, and vaccine availability will influence policy choices for booster vaccination.
Article
Medicine, General & Internal
Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli, Abdulwahab Alsayegh, Usama Aldallal, Mariam Alsayegh, Preethi Cherian, Irina Alkhair, Thangavel Alphonse Thanaraj, Arshad Channanath, Ali A. Dashti, Anwar Albanaw, Hamad Ali, Mohamed Abu-Farha, Jehad Abubaker, Fahd Al-Mulla
Summary: This study investigated the immunogenicity of the BNT162b2 vaccine booster dose in patients with inflammatory bowel disease (IBD) on infliximab combination therapy. The results showed that patients who received the third dose of the vaccine had significantly higher concentrations of SARS-CoV-2 antibodies compared to those who received the second dose only.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Byung Ok Kwak, Young Se Kwon, Young Jin Hong, Seon Hee Shin, Byung Wook Eun, Young Min Ahn, Hwang Min Kim, Nam Hee Kim, Dong Hyun Kim
Summary: The study aimed to investigate the immunogenicity and safety of the third booster dose of the inactivated JE vaccine in Korean children, and found that it is both safe and effective in boosting immunity.